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POLYMORPHOUS LIGHT ERUPTION
A DISCUSSION OF ITS PATHOGENESIS AND THE THERAPEUTIC ACTION OF THE
ANTIMALARIALS IN THIS DISEASE *
BERTRAM SHAFFER, M.D., D.Sc. (Med.), MILTON M. CAHN, M.D. AND EDWIN J. LEVY, M.D.
Polymorphous light eruption is a cutaneous
symptom complex which Lamb et al. (1) have
divided into four separate but sometimes over-
lapping categories; namely, the contact eczema-
tous type, the prurigo-like variety, the plaque-
like picture and the erythema perstans eruption.
Irrespective of the morphologic designation
all cases of polymorphous light eruption occur
on light-exposed portions of the skin, arc pre-
cipitated and perpetuated by exposure to sun-
light and improve promptly when light protec-
tive measures arc used. In the Middle-Atlantic
States winter sunlight is incapable of inducing
this reaction.
The plaque-like lesions not infrequently
resemble closely the cutaneous manifestations of
subacute lupus crythcmatosus, but systemic
signs, such as fever, increased sedimentation
rate, the LE test, and lcukopenia arc absent in
the former disease and the lesions do not undergo
atrophy. However, the histologic picture of
polymorphous light eruption is quite similar to
that of lupus crythcmatosus and it is not possible
in most cases for the histologist to differentiate
between the two diseases solely on microscopic
features. We have felt that in some instances,
the differential diagnosis is not always possible
and that occasionally an eruption starting out
with the definitive features of polymorphous
light eruption may end up as unqualified lupus
erythcmatosus (2).
We have been intrigued by problems connected
with an understanding of the pathogcncsis of
polymorphous light eruption; and also, in view
of the favorable effects of antimalarials in this
disease (3, 4), the mechanism by which these
drugs are able to act.
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Our studies have lead us to believe that
polymorphous light eruption is very often an
allergic reaction to light involving a specific
wave band. Since allergy may be defined as an
acquired specific change in capacity to react
involving the antigen-antibody mechanism, it
seemed worthwhile to correlate this definition
with our knowledge of this disease.
The following features of polymorphous light
eruption as it relates to allergic disease are
detailed below.
(1) ALLERGY IS ACQUIRED
Polymorphous light eruption is an acquired
disease. No family relationship is involved.
(2) ALLERGy INVOLVES A CHANGE IN CAPACITY
TO EEACT
The victims of polymorphous light eruption
always give a history of normal reactivity to
sunlight prior to the onset of their disease but
they, thereafter, respond in an altered fashion
involving a qualitative change in the capacity of
the skin to respond to light.
At this point it is well to emphasize that
polymorphous light eruption is not just light
sensitivity. Except for the contact cczcmatous
type (which is rare in our experience), the lesions
of polymorphous light eruption do not at all
resemble sunburn erythcma either clinically or
histologically.
Fig. 1 illustrates some of the differences of the
reaction of the skin of the back to five crythcma
doses of hot quartz ultraviolet light on normal
adult white volunteers and on white patients
with polymorphous light eruption. Approxi-
mately 40% of patients with polymorphous
light eruption respond with specific positive
light tests having typical clinical and histologic
features corresponding to the clinically induced
disease. In no case had these test sites pre-
viously been involved with clinically developed
polymorphous light eruption.
In a normal person erythcma reaches its peak
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Erythema Normal P.L.E.
Time 24—48 hrs. 48—96 hrs.
Degree less more
Duration 3—5 days 7—14 days
Pigment + —
Papules — +
Reaction at distance... — +
FIG. 1. Reactions of "Virgin" Skin to H.Q.
in 24 to 48 hours and it continues for three to five
days after which it is followed by scaling and
pigmentation. On the other hand, in patients
with polymorphous light eruption who show a
positive specific test to this disease on "virgin"
skin, the erythema begins in six to eight hours,
reaches its peak in 48 to 96 hours, persists for
seven to 14 days with an intensity much greater
than that of the normal erythema, after which it
is replaced by a papular inflammatory reaction
which is clinically and instologically similar to
that seen in the spontaneously developed disease.
Pigmentation fails to appear in these areas.
(These changes are shown in the illustrations
facing page 356.)
(3) ALLERGY IMPLIES THE ACTION OF A SPECIFIC
INCITANT
We have found by clinical, as well as by experi-
mental investigations involving the use of artifi-
cial ultraviolet light with filters, that in our
cases, at least, (which, by the way, were all of
the pruriginous and plaque type) only light
between 2900 and 3000 A was capable of pro-
ducing this reaction (5). (There have been re-
ported, however, a few authenticated cases
where other spectral bands appear to have been
involved (6) ). Since only light of a narrow
spectral range elicits this disease it obviously is a
specifically induced reaction.
(4) AN ANTIGEN-ANTInonv EEACTION Is INvoLvED
In patients with polymorphous light eruption
we have observed that an occasional test site
exposed to hot quartz ultraviolet light, showing
either a normal response or an eruption with the
features of polymorphous light eruption, would
flare up again with the specific manifestations of
the latter condition when the patient developed
his usual eruption upon clinical exposure to
sunlight even though the test site had been
covered to protect it against light exposure (7).
The specificity of the precipitating light band
plus the reaction at a distance can hardly be
explained on any basis other than an antigen-
antibody mechanism. Presumably a pro-antigen
already present in the skin absorbs specifically
the selected light energy and is thus converted
into an active antigen. This enters the circulation
and then reacts with a fixed antibody at the
previously sensitized site. While this hypothesis
Jacks complete experimental confirmation, it
appears to us to explain best the phenomena
that we have observed.
The experimental demonstration of an allergic
mechanism in this case is at least as complete
as is found in other eases of generally accepted
allergic reactivity such as, for instance, certain
cases of drug eruptions and erythema nodosum.
In connection with these studies, we have
performed passive transfer tests using sera from
13 patients with polymorphous light eruption
at the height of their disease. The recipients
were normal people who were challenged at the
test sites with hot quartz ultraviolet light and
normal sunlight. All these tests were negative.
Epstein (8) succeeded in getting two positive
tests with sunlight and one questionable positive
test with artificial ultraviolet light out of six
cases using tins technic. It is possible that
passive transfer tests using concentrated white
blood corpuscles may be more successful.
Other features of allergic reactivity in polymor-
phous light eruption which we have noted
included (1) the clinically observed long re-
fractory period, (i.e., the time between the
patient's first exposure to ultraviolet light and
the beginning of sensitization), (2) the incuba-
tion period of 7—14 days as demonstrated on
experimental sites, (3) the reaction time of six
to 24 hours on clinical exposures as seen in al-
ready sensitized skin. It is noteworthy that these
periods are quite similar in duration to those
found in other types of allergic manifestations
such as contact eezematous dermatitis and
drug eruption.
We have pursued other studies in the hope of
elucidating the nature of this disease. These have
included spectrophotometrie and eleetrophoretie
examinations of the sera of five patients with
polymorphous light eruption (9), as well as
the examination of the urine for delta-amino
laevulie acid (10), a photosensitizing substance
found in the urine of patients with congenital
POLYMORPHOUS LIGHT ERUPTION 365
porphyria. No constant or characteristic devia-
tions from normal were found in patients with
polymorphous light eruption insofar as these
examinations were concerned.
The beneficial effects of the antimalarial drugs
namely, quinacrine, chloroquine, hydroxychloro-
quinc and amodiaquin on polymorphous light
eruption are now well documented (2, 3). It
was natural at first to assume that the antimalar-
ials acted as a sort of light filter and that they
prevented the ultraviolet radiation from reach-
ing a reacting system in the shin. Our own
experiments, however, did not bear this out.
Most of our cases of polymorphous light eruption
reacted to the spectral band between 2900—3100
A. This is the same light band that is largely
responsible for sunburn erythema.
To evaluate the possible role of antimalarials
as light barriers the following experiments were
performed: normal white male volunteers were
given exposures to ultraviolet light both from
natural as well as artificial sources, with and
without the ingestion of doses of ehloroquine
comparable to those used in the clinical treat-
ment of polymorphous light eruption. The follow-
ing dosage schedule was used: ehloroquine
diphosphate (Aralen), 250 mg. twice a day for
one week, then 250 mg. a day for three weeks.
In all eases it was found that ehloroquine taken
prior to the exposure to ultraviolet light was
unable to modify the normal erythema reaction.
This would seem to indicate strongly that
the antimalarials did not interfere with the
absorption of ultraviolet light in the spectral
band specifically responsible for both polymor-
phous light eruption (as observed in our series)
and normal sunburn (5).
It was, furthermore, shown that the absorption
maxima of the antimalarials differ, and in no
ease are these in the sunburn spectral range. It is
impossible, therefore, to explain the action of the
antimalarials as a physical barrier to the passage
of ultraviolet light.
Various types of skin reactions including
eezematous contact dermatitis (due to poison
ivy antigen, pentadeeyleateehol), urtiearial
lesions (due to histamine) and papular inflam-
matory responses (due to triehophyton) were
produced on volunteers. After these individuals
were given ehloroquine it could be shown in no
ease was this drug able to modify the above
reactions. In contrast to these studies, we have
demonstrated that ehloroquine was able to
suppress completely the specific positive skin
test to ultraviolet light in patients with poly-
morphous light eruption.
We have concluded, therefore, that ehloro-
quine, and presumably other antimalarials, in
some unknown manner was able to alter and
suppress specifically the unique inflammatory
reaction that constitutes polymorphous light
eruption, that it had no effect on reactions to
non-specific agents (i.e., those not causing
polymorphous light eruption) giving rise to
experimental eezematous, urtiearial or papular
inflammatory reactions.
To substantiate further this thesis, attempts
were made to measure quantitatively the
amount of antimalarial present in separated
epidermis and eorium, and, at the same time,
to observe the spectral absorption characteristics
of these tissues (11). Specimens were taken from
normal white, male volunteers before and after
the ingestion of antimalarials. The dosage sched-
ules were as follows: Quinacrine dihydroehloride
(Atabrine), 100 mg. three times a day for one
week, then 100 mg. a day for three weeks.
Chloraquine diphosphate (Aralen), 250 mg.
twice a day for one week, then 250 mg. a day for
three weeks. Hydroxyehloroquine sulphate (Pla-
quenil), 200 mg. twice a day for one week, then
200 mg. a day for three weeks. Amodiaquin
(Camoquin), 200 mg. a day for one week, then
200 mg. a day for three weeks.
In all eases measurable quantities of anti-
malarials were detected in the epidermis and in
the eorium. Much to our surprise the quantity
of the antimalarials in the epidermis was con-
siderably higher than in the corium by a ratio
of 5-15 :1. Quinaerine had an average concentra-
tion of 19.2 micrograms per gram of wet epider-
mis, while the figure for amodiaquin was found
to be 31.6 micrograms per gram. The readings
of hydroxyehloroquine and ehloroquine ivere 22.3
and 25.8 respectively. If we assume that the
specific gravity of the epidermis is one, with
a thickness of 0.1 mg., the actual amount of
antimalarial present may be in the neighborhood
of 0.2 microgram in each square em. of epi-
dermis. This is an infinitesimal amount and
is certainly not sufficient to act significantly as
a sun barrier.
When specimens of separated epidermis and
eorium were examined spectrophotometrieally,
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it was discovered that the presence of the anti-
malarials did not modify in the least the normal
spectral characteristics of these tissues. This,
again, emphasized the fact that the antimalar-
ials actually present in these tissues had little
absorptive qualities insofar as ultraviolet light
was concerned.
CONCLUSIONS
(1) Evidence is presented to indicate that
many cases of polymorphous light eruption are
in fact allergic reactions to ultraviolet light of a
specific spectral range, namely 2900—3100 A.
(2) The antimalarials tend to be concentrated
in the epidermis Vie a vis the corium in a con-
centration of 5—15:1.
(3) The antimalarials in these tissues do not
act as a significant light barrier to the passage
of ultraviolet light.
(4) They have no effect in suppressing normal
reactions due to nitraviolet light nor do they
modify ordinary eczematous, urticarial or
papular inflammatory reactions.
(5) The antimalarials affect favorably the
manifestations of polymorphous light eruption
by specifically suppressing the unique reaction
that constitutes this disease.
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